Measure Exposure Of Tanezumab In Healthy Volunteers When Administering The Drug Subcutaneously

Completed · Phase 1

Conditions studied: Healthy Volunteers

In brief

The hypothesis of this study is that subcutaneous administration of tanezumab results in lower drug exposure compared to intravenous administration of tanezumab.

Key facts

Study ID

NCT00788294

Run by

Pfizer

People needed

76

Starts

2008-11-01

Expected to finish

2009-06-01

Last updated by the study team

2020-10-06

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Generally healthy
• BMI of 18-30 kg/m2
• more than 50 kg bodyweight.

You may not qualify if…

• Pregnant
• exposure to biologic type drugs within the last 3 months
• history of allergic or anaphylactic reaction to a biologic drug
• use of tobacco- or nicotine containing products that is more than what is in 5 cigarettes per day
• excessive alcohol use.

Where it is running

• Pfizer Investigational Site — Cypress, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.